Evidence map›Paper›PMID 42904293›Full record

ArticleCureus2026

Anticoagulation Monitoring in Recurrent Venous Thromboembolism Associated With Antiphospholipid Antibodies and Subsequent Heparin-Induced Thrombocytopenia.

George Bechir

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

George BechirInternal Medicine, Franciscan Health, Munster, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A woman in her 20s with class III obesity and strongly positive antiphospholipid antibodies developed phlegmasia cerulea dolens and a new pulmonary embolus after recent catheter-directed thrombolysis. Before the first documented heparin administration, activated partial thromboplastin time was 95.5 s and international normalized ratio was 1.5. Eight subsequent paired samples showed activated partial thromboplastin times of 176 s to over 200 s with heparin anti-Xa activity of 0.20-0.66 IU/mL. Lupus anticoagulant testing was uninterpretable during anticoagulation, and international normalized ratio reliability was not independently established. Later thrombocytopenia prompted repeat heparin-induced thrombocytopenia testing despite an earlier negative result; a strongly positive immunoassay supported the treating team's diagnosis and transition to fondaparinux. This case illustrates the importance of selecting appropriate anticoagulation monitoring from the outset and reassessing heparin-induced thrombocytopenia when the clinical picture changes. Whether assay interference contributed to recurrent thrombosis remains unresolved.

Indexed as

activated partial thromboplastin timeanticoagulation monitoringantiphospholipid antibodiesheparin-induced thrombocytopeniavenous thromboembolism

Identifiers

PMID42904293
PMCPMC13682851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.